Cara Therapeutics Announces Successful Completion of Phase I trial of novel analgesics.

Cara Therapeutics Announces Successful Completion of Phase I trial of novel analgesics, CR845Cara Therapeutics announced completion of a Phase I clinical trial for the second generation, peripherally acting kappa opioid agonists, acute in development for the treatment and chronic pain. The drug candidate was safe and well tolerated after intravenous infusion and led probably be associated with clinical analgesic effect on plasma levels of CR845. In addition, CR845 infusion triggered a quantitative endocrine biomarkers tested the peripheral kappa opioid receptor activation at the lowest dose.

The company plans its intravenous formulation of CR845 in Phase II trials later to advance in 2008. Based on the demonstrated safety, tolerability and bioactivity of this formulation in Phase I, Cara will continue to develop its oral formulation of CR845 for advancement into Phase I.A View of demographic changes has the redistribution of work over the service life naturally has become an economic necessity. Social Sciences continue to make an valuable contribution to fathom of the Conditions Conditions and obstacles for the design of new life – Rates. ####Original publication:J. Vaupel and E. Loichinger point reallocation of labor into aging Europe, Science.